Leukotriene modifiers in the treatment of asthma in children.

abstract：:In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

journal_title：Therapeutic advances in respiratory disease

authors： Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

更新日期：2014-06-01 00:00:00

abstract：:Within telehealth there are a number of domains relevant to pulmonary care: telemonitoring, teleassistance, telerehabilitation, teleconsultation and second opinion calls. In the last decade, several studies focusing on the effects of various telemanagement programs for patients with chronic obstructive pulmonary disea...

journal_title：Therapeutic advances in respiratory disease

authors： Vitacca M,Montini A,Comini L

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

journal_title：Therapeutic advances in respiratory disease

authors： Xu L,Yi M,Tan Y,Yi Z,Zhang Y

更新日期：2020-01-01 00:00:00

abstract：:Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategi...

journal_title：Therapeutic advances in respiratory disease

authors： Warner JO

更新日期：2017-04-01 00:00:00

abstract：OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

journal_title：Therapeutic advances in respiratory disease

authors： Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

更新日期：2007-12-01 00:00:00

abstract：:To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

journal_title：Therapeutic advances in respiratory disease

authors： Selroos O,Borgström L,Ingelf J

更新日期：2009-04-01 00:00:00

abstract：:It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

journal_title：Therapeutic advances in respiratory disease

authors： Hudmon KS,Corelli RL,Prokhorov AV

更新日期：2010-02-01 00:00:00

abstract：:Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

journal_title：Therapeutic advances in respiratory disease

authors： Brienza NS,Amor-Carro O,Ramos-Barbón D

更新日期：2011-02-01 00:00:00

abstract：:Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

journal_title：Therapeutic advances in respiratory disease

authors： Villanueva N,Bazhenova L

更新日期：2018-01-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

journal_title：Therapeutic advances in respiratory disease

authors： Stream AR,Bull TM

更新日期：2012-10-01 00:00:00

abstract：OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

journal_title：Therapeutic advances in respiratory disease

authors： Iftikhar IH,Musani AI

更新日期：2015-10-01 00:00:00

abstract：:Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

journal_title：Therapeutic advances in respiratory disease

authors： Hurley M,Smyth A

更新日期：2012-12-01 00:00:00

abstract：:Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

journal_title：Therapeutic advances in respiratory disease

authors： Ozdemir C

更新日期：2009-10-01 00:00:00

abstract：:Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' d...

journal_title：Therapeutic advances in respiratory disease

authors： Malerba M,Nardin M,Santini G,Mores N,Radaeli A,Montuschi P

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

journal_title：Therapeutic advances in respiratory disease

authors： Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

更新日期：2018-01-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

journal_title：Therapeutic advances in respiratory disease

authors： de Blasio F,Polverino M

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS pers...

journal_title：Therapeutic advances in respiratory disease

authors： Chiu LC,Lin SW,Liu PH,Chuang LP,Chang CH,Hung CY,Li SH,Lee CS,Wu HP,Huang CC,Li HH,Kao KC,Hu HC

更新日期：2020-01-01 00:00:00

abstract：:Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

journal_title：Therapeutic advances in respiratory disease

authors： Derom E,Brusselle GG,Joos GF

更新日期：2019-01-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

journal_title：Therapeutic advances in respiratory disease

authors： Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

更新日期：2012-04-01 00:00:00

abstract：OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

journal_title：Therapeutic advances in respiratory disease

authors： Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

更新日期：2020-01-01 00:00:00

abstract：:Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

journal_title：Therapeutic advances in respiratory disease

authors： Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is unclear. The purpose of this study was to examine the efficacy of PM...

journal_title：Therapeutic advances in respiratory disease

authors： Ichiyasu H,Horio Y,Masunaga A,Migiyama Y,Sakamoto Y,Jodai T,Ideguchi H,Okabayashi H,Hamada S,Yoshida C,Hirosako S,Okamoto S,Kohrogi H

更新日期：2017-07-01 00:00:00

abstract：OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

journal_title：Therapeutic advances in respiratory disease

authors： Scichilone N,Scalici V,Arrigo R,Bellia V

更新日期：2013-08-01 00:00:00

abstract：OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

journal_title：Therapeutic advances in respiratory disease

authors： Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

更新日期：2020-01-01 00:00:00

abstract：:The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

journal_title：Therapeutic advances in respiratory disease

authors： Farsalinos K

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

journal_title：Therapeutic advances in respiratory disease

authors： Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

journal_title：Therapeutic advances in respiratory disease

authors： Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

更新日期：2013-10-01 00:00:00

abstract：:The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

journal_title：Therapeutic advances in respiratory disease

authors： Porcel JM

更新日期：2018-01-01 00:00:00

abstract：:Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...

journal_title：Therapeutic advances in respiratory disease

authors： Namazy JA,Schatz M

更新日期：2014-08-01 00:00:00